| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 817001 | 25 ug | $145 | ||
| 817002 | 100 ug | $295 |
| Application | ELISA, BLI |
|---|---|
| Format | Liquid, Purified |
| Expression Host | CHO |
| Target Name | CD80, B7-1, B7, BB1 |
| Species | Human |
| Sources | Recombinant Human B7-1 (CD80) (Val35-Asn242) with C-terminus Fc-tag is expressed in CHO cell. |
| Accession Number | Q68D85 |
| Molecular Weight | The protein has a predicted molecular weight of 50.1 kDa. Under DTT-reducing conditions, it migrates at approximately 65 kDa on SDS-PAGE. |
| Affinity Tag | C-Fc |
| Purity | >95% based on SDS-PAGE under reducing condition |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.22 µm filtered |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability. |
B7-1, also known as CD80, is a cell surface glycoprotein in the immunoglobulin superfamily, expressed on activated B cells, macrophages, and dendritic cells. It interacts with the costimulatory receptors CD28 and CTLA-4 on T cells, playing a pivotal role in regulating T cell activation, tolerance, cytokine production, and the generation of cytotoxic T lymphocytes. Through its interactions with CD28 and CTLA-4, CD80 is involved in both enhancing and inhibiting immune responses, thereby maintaining immune balance. This B7/CD28/CTLA-4 pathway is crucial for controlling immune function and is considered a promising target for therapeutic interventions in autoimmune diseases and cancer.
